Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use
In a report published Monday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ: OMER).
In the report, Wedbush noted, “A recent conversation with a high-volume cataract surgeon on OMS302's potential use enhances our outlook for Omeros. The FDA is cracking down on sterility of topical solutions used during intraocular lens replacement surgery. We recently had a conversation with a high-volume cataract surgeon about the changing regulatory landscape following sterility issues at compound pharmacies. The FDA has indicated that each patient must be given a separate bottle for topical NSAIDs and mydriatic agents. In addition, surgeons are no longer allowed to mix their own homebrews of these agents for use during surgery—a common practice.”
Omeros Corporation closed on Friday at $5.09.
Latest Ratings for OMER
|Jun 2016||Cantor Fitzgerald||Initiates Coverage on||Buy|
|Apr 2016||Roth Capital||Terminates||Buy|
|Aug 2015||Roth Capital||Initiates Coverage on||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.